Title: Mapping the Immune Environment in Clear Cell Renal Carcinoma by Single-Cell Genomics

**Authors:** Nick Bocherding1,2†, Ajaykumar Vishwakarma3,4,7†, Andrew P. Voigt2, Andrew Bellizzi5, Jacob Kaplan5, Kenneth Nepple6, Aliasger K. Salem3, Russell W. Jenkins4, 7 \*, Yousef Zakharia6, 8\*, Weizhou Zhang9 \*

**Affiliations:**

1 Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA

2 Medical Science Training Program, University of Iowa, Iowa City, IA, USA

3 Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA

4 Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

5 Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

6 Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

7 Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA

8 Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

9 Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, USA

† Authors contributed equally to this work

\* These authors jointly supervised this work

[rjenkins@mgh.harvard.edu](http://rjenkins@mgh.harvard.edu) (R.W.J)

[yousef-zakharia@uiowa.edu](mailto:yousef-zakharia@uiowa.edu) (Y.Z)

[zhangw@ufl.edu](mailto:zhangw@ufl.edu) (W.Z)

**Abstract**:

Clear cell renal cell carcinoma (ccRCC) is one of the most immunologically distinct tumor types due to high response rate to immunotherapies, despite low tumor mutational burden. To characterize the tumor immune microenvironment of ccRCC, we applied single-cell-RNA sequencing (SCRS) along with T-cell-receptor (TCR) sequencing to map the transcriptomic heterogeneity of 25,688 individual CD45+ lymphoid and myeloid cells in matched tumor and blood from three patients with ccRCC. We also included 11,367 immune cells from four other individuals derived from the kidney and peripheral blood to facilitate the identification and assessment of ccRCC-specific differences. There is an overall increase in CD8+ T cell and macrophage populations in tumor-infiltrated immune cells compared to normal renal tissue. We further demonstrate the divergent cell transcriptional states for tumor-infiltrating CD8+ T cells and identify a *MKI67*+ proliferative subpopulation being a potential culprit for the progression of ccRCC. Using the SCRS gene expression, we found preferential prediction of clinical outcomes and pathological diseases by subcluster assignment. With further characterization and functional validation, our findings may reveal certain sub-populations of immune cells amenable to therapeutic intervention.

**Introduction**

ccRCC is the most common type of renal cell carcinoma, comprising more than 70% of all renal cancers.1 ccRCC represents an immune sensitive tumor type and is known for early advances in systemic immunotherapy using T cell proliferation cytokine IL-2 and interferon (IFN)-α2b therapy.2 Recent novel immunotherapies targeting immune checkpoints as standard of care have transformed the treatment paradigm of ccRCC.3,4 However, a substantial subset of renal cancer patients do not respond to these therapies and patients who initially do respond eventually progress.5,6 Cytotoxic tumor-infiltrating lymphocytes (TILs), in particular CD8+ T cells are key effectors of the adaptive anti-tumor immune response7 and abundance of CD8+ T cells in solid cancers is generally associated with better survival in cancer patients.8–11 However, in ccRCC, immune cell abundance is inversely correlated with survival, specifically TILs including CD8+ T cells.12–15 Biomarker analysis results from recent clinical trials also supported the negative prognostic significance of T cell infiltrates in the absence of immunotherapy within treatment-naïve ccRCC patients.16,17 Other abundant immune players in the ccRCC tumor microenvironment include monocytes, dendritic cells, and TAMs18 that are now just starting to be studied.

Quantifying and inferring immune cell abundance from transcriptional analysis of bulk tumor samples is inadequate to provide a clear picture of the immune cell types.19,20 While these studies are suggestive, they lack single cell resolution for characterizing heterogeneous cell subpopulations that ultimately shape anti-tumor response, as has been demonstrated in breast cancer and melanoma.21,22 Single-cell methodologies including flow cytometry, immunohistochemistry, and mass cytometry14,18,23 have revealed immune cell states in ccRCC as discrete phenotypes when in vivo they typically display diverse spectrum of differentiation or activation states. Also, these methods require use of antibody panels targeting known immune cell components, and by design are not capable of identifying novel sub-populations of cells. SCRS has enabled comprehensive characterization of heterogeneous lymphoid and myeloid immune cells in several cancers,24–27 providing an unbiased approach to profiling cells and enabling molecular classification of different subpopulations and identification of novel gene programs. Transcriptomic mapping of T lymphocytes coupled with TCR sequencing allows additional measurement of clonal T cell response to cancer at an unprecedented depth.28,29

Here, we report the single-cell profiling of the immune landscape in ccRCC mapping 25,688 of immune single cells (5’-sequencing and recombined V(D)J region of the T cell receptor) in matched tumor samples and peripheral bloods from three treatment-naïve ccRCC patients. We further integrated an additional, 11,367 immune cells isolated from peripheral blood and renal parenchyma30 providing controls to evaluate tumor-specific transcriptional and clonal changes in immune populations at the single-cell level. Analysis of tumor-infiltrating T cells demonstrated distinct expression changes compared to peripheral blood and normal renal parenchyma. Clonal structure of T cells differed – with marked expansion seen in CD8+ T cells but not CD4+ T cells – and was associated with transcriptional patterning revealed by cell trajectory analysis. In myeloid cells, we observed an overall increase in macrophage populations with mixed polarization across patients. Predictive models derived from the CD8+ T cells and TAMs identified worse overall survival associated with proliferative CD8+ T cells and *CD207*+ TAMs. This represents the first such report of the immune landscape of ccRCC using SCRS for both transcriptional and clonal assessment.

**Results**

*Single-cell expression profiling of immune cells in ccRCC*

In order to define the immune microenvironment of human ccRCC, we performed SCRS on flow-sorted lymphoid and myeloid cells from tumors and matched peripheral blood from three treatment-naïve ccRCC patients. The general workflow for isolation and sequencing is available in Supplemental Figure 1. To these samples, we added immune cells from peripheral blood and normal renal parenchyma30 to obtain an integrated UMAP projection of 22 clusters across 37,055 primary immune cells (Figure 1a). Across the three tissues, peripheral blood (n=21,160), tumor (n=12,239) and normal kidney (n=3,556), we found a number of clusters – notably clusters 0, 1, 3 and 7 – sharing similar gene expression (Figure 1b). Despite the integration of sequencing runs to reduce tissue-type divergence, each tissue type had enrichment for distinct clusters: peripheral blood formed the majority of Cluster 2, tumor tissues were enriched within Clusters 14, 17, 18, and 19, and normal kidney was enriched within Cluster 11. Based on gene expression, we assigned cell lineages to each cluster using a three-method approach: 1) expressions of canonical markers for T cells (*CD3E*, *CD8A*, *CD4*, and *IL7R* or CD127), B cells (*CD19* and *MS4A1*), myeloid cells (*CD14* and *FCGR3A* or CD16) and natural killer (NK) cells (*KLRD1* and *NKG7*) (Figure 1c), 2) correlations with gene signatures derived from purified cell populations deposited by ENCODE37 (Figure 1d), and 3) assignments of T cell clonotypes based on the TCR sequencing. Based on these approaches we annotated clusters as monocytes (Clusters 0, 5, 11, 12, and 16), CD4+ T Cells (Clusters 4, 6, 10, 13, 15, and 20), CD8+ T cells (Clusters 1, 8, 9 and 17), NK cells (Clusters 3 and 7), B cells (Cluster 2), macrophages (Cluster 14) and dendritic cells (DC, Clusters 18 and 19) (Figure 1e). We also examined the relative proportion of cell types comprising the sequencing runs by tissue type (Figure 1e). We observed a decrease of CD4+ T cells and B cells within normal kidneys or tumors relative to peripheral blood (Figure 1e). Conversely and as expected, we also found an increase of CD8+ T cells and macrophages in tumors relative to peripheral bloods (Figure 1e). Using highthroughput immunohistochemistry on paired normal and tumor tissue, we found similar trends of increased CD8+ and decreased CD4+ T cells from tumor versus normal renal tissue derived from the ccRCC patient samples (Supplemental Figure 2).

*Preferential overlap between peripheral blood and tumor CD8+ T lymphocytes*

With the extensive literature demonstrating the role of TCR expansion in anti-tumor immunity and immunotherapy,11 we first wanted to investigate the dynamics of CD4+ and CD8+ T cell clonal species in ccRCC. Using our previously described scRepertoire software,38 we assigned productive TCR sequences for TCRA and TCRB and defined clonotypes by the combination of both the genes and nucleotide sequences. For the identified T cells in ccRCC patients, recovering of at least one TCR chain, ranged from 74.8% to 87.6% after filtering and clonotype reconstruction. The complete table of clonotype information for the ccRCC samples is available in Supplemental Data 1. T cell clonotypes had a clear distribution along the UMAP, with principal enrichment within Clusters 1, 4, 6, 8, 9, 13, 15, 17 and 20 (Figure 2a). Cluster 21 was the exception for T cells, consisting of an estimated 19.6% of doublets and clustering with B cells, possibly indicating the cell-cell interaction of B and T cells and were excluded from further T cell analyses. The frequency of clonotypes was assigned across patient samples, allowing for the quantification of clonotype numbers in the context of individual patients. We observed an increase in clonotype frequency principally in the CD8+ T cell clusters (Figure 2a). There were expanded clonotypes in assigned NK cell clusters 3 and 7, however, these clonotypes were also seen in other T cell clusters, suggesting a possible subset of T cells with overlapping gene expression with NK cells or NK T cells. Single clones and clones with 1-5 copy numbers were seen across myeloid clusters (Figure 2a), which may be a result of partial loss of finer gene expression differentiation during the expression integration.41 Separating the T cell classes, we noted a stark difference in clonotype space occupied by the top 10 clones in the CD8+ T cells compared to CD4+ T cells across ccRCC patients (Figure 2b). This trend was consistent between the tumor-infiltrating and peripheral blood CD8+ T cells (Figure 2b). We next asked if this consistency in CD8+ T cell expansion was a result of shared expanded clonotypes between tumor and peripheral blood. We found a relative patient-specific increase in shared clonotypes in CD8+ T cells compared to CD4+ T cells (Figure 2c). We also noted that there was minimal overlap between patient clonotypes for both CD8+ and CD4+ T cells (Figure 2c).The patient-specific overlap of CD8+ clonotypes showed relatively larger pools in peripheral blood clonotypes contributing to the tumors (Figure 2d). Interestingly, Patient 3 – with the more advanced tumor stage (pT3a compared to T1 of Patient 1 and 2) – showed expansion in tumor-specific clonotypes that was not seen in the blood (Figure 2d). In the more advanced Patient 3 ccRCC, two clonotypes accounted for a total of 619 CD8+ T cells and were distributed across UMAP clusters (Figure 2e), which supports the notion that T cell clonotype is neither a determinant for UMAP clustering nor for functional indication. This compartmentalization of clonotypes associated with exhausted gene expression may reflect origin of the expansion in the tumor itself.42

*CD8+ T cells in ccRCC tumors exhibit a transcriptional continuum with distinct populations*

Sub-clustering of CD8+ T cells revealed 8 distinct clusters (Figure 3a) with relative tissue-specific distribution (Figure 3b). To understand the distribution of these new CD8+ subclusters along the UMAP, we first examined the relative percent of single-cells represented in each cluster by tissue type. Tissue-infiltrating CD8+ T cells (both tumor and normal kidney) comprised the majority of CD8\_0, CD8\_1, CD8\_3, CD8\_5, CD8\_6 and CD8\_7. Only Clusters CD8\_2 and CD8\_4 had increased relative levels of peripheral blood cells (Figure 3b). Going from right to left across the x-axis of the UMAP, there is a change in tissue-specific contribution starting from peripheral blood (right) to kidney (middle) to increasing levels of ccRCC tumor CD8+ T cells (left), which may represent the process of tissue infiltration itself. Within SCRS literature, there are concerns for variations in cell cycle leading to increased heterogeneity or obscure subpopulations,43 however proliferation of CD8+ T cells is an important surrogate marker of anti-tumor immune response.7 We next examined the variation in proliferative gene signatures, finding a similar distribution to the tissue-type with increasing cells in S or G2M phases from right to left, peaking with Cluster CD8\_6 (Figure 3c).

In order to better characterize the CD8+ clusters, we used canonical and differential T cells markers to examine gene expression differences along the UMAP (Figure 3d) with several patterns. The first pattern was the discovery of a naïve *CCR7*+ *SELL*+ *TCF7*+ being seen in CD8\_4 (Figure 3d). Looking for effector CD8+ T cells, we next observed two populations of *IFNG*+ *PRF1*+ T cells, principally in CD8\_1 and CD8\_0 (Figure 3d). The latter also expressed immune checkpoints, such as *CTLA4*, *HAVCR2*, *PDCD1*, and *TIGIT* (Figure 3d). These immune checkpoints were expressed at more moderate levels in both CD8\_5 and CD8\_6; however, CD8\_6 exclusively expressed a number of proliferation markers, such as *CDK1*, *MKI67*, *STMN1*, and *TOP2A* (Figure 3d). In order to examine gene expression patterns above single or selected genes, we used slingshot 39 to build minimum spanning trees between subclusters, generating curves based on the most varied genes (Figure 3e). We identified 5 distinct curves (labeled B1 to B5) with the origin in the *CCR7*+ *SELL*+ *TCF7*+ CD8\_4. With the exception of B1 extending into CD8\_2, the remaining curves graphed along a similar trajectory with a common node of CD8\_1 and branching at distinct clusters with increased levels of tumor-infiltrating CD8+ T cells (Figure 3e). These curves also varied by CD8+ T clonotypes based on TCR sequencing, with the root having no clonal expansion and the B3, B4 and B5 curves terminating into regions with higher levels of clonal expansion compared to B1 or B2 (Figure 3e). This clonotype relationship was also observed in specific clonotype sequences with overlapping clonotypes seen in subclusters CD8\_0, CD8\_6, CD8\_5 and CD8\_3 (Figure 3f). In contrast, CD8\_7 had minimal overlapping clonotypes with other subclusters (Figure 3f). This relationship was seen also independent of the individual patient sequenced (Supplemental Figure 3). In order to assess possible functional differences based on these branching, we performed gene set enrichment analysis (Figure 3g).44 As expected based on the immune checkpoint inhibitors expression (Figure 3d), Clusters CD8\_0 and CD8\_5 showed increased terminal differentiation and exhaustion (Figure 3g). Cytolytic gene enrichment was seen in CD8\_1, the PRF1+ IFNG+ population lacking immune checkpoints (Figure 3g). The highly proliferative CD8\_6 population was enriched for metabolic activity, such as the tricarboxylic acid cycle and glycolysis, and DNA repair (Figure 3g). The B2 curve termination cluster, CD8\_7, has preferential enrichment of cytokine signaling, such as IL-2/STAT5, TGFβ, and type 1 interferon (Figure 3g). With immune checkpoint inhibitor responsiveness associated with distinct CD8+ T cell populations,22 we next examined enrichment of signatures associated with response or nonresponse to anti-PD-1 therapies (Figure 3h). Using the ordinal construction of the trajectories, we created a pseudotime variable for cells, allowing us to see the difference in the enrichment along the curves. This approach found an overall enrichment in gene expression associated with responsiveness to anti-PD-1 at the terminal points of curve B2 and midpoints of B3, B4 and B5, corresponding to cells in CD8\_1 (Figure 3h, blue lines). Likewise, we observed an overall increase in gene expression associated with no response or progression on anti-PD-1 therapy at the terminal points of curves B3, B4, and B5 (Figure 3h, red lines).

*Single-cell CD4+ T cell characterization in ccRCC identifies disparate intratumoral populations.*

CD4+ T cells can influence cancer pathogenesis in various ways, either directly through cytolytic mechanisms or indirectly by modulating the tumor immune microenvironment. Subclustering of CD4+ T cells revealed 9 distinct clusters (Figure 4a), with a similar pattern – as seen in CD8 T cells – of tissue distribution with predominantly peripheral blood CD4+ T cells on the right leading to tissue-infiltrating CD4+ T cells on the left (Figure 4b). The CD4\_8 was composed solely of peripheral blood cells from the healthy donor and was eliminated from the remaining analysis. Like the CD8+ T cells, we next examined the canonical and differential T cell markers along the UMAP (Figure 4c). The first pattern that emerged was a naïve *CCR7*+ *SELL*+ *TCF7*+ being seen in CD4\_1 and CD4\_3 (Figure 4c). Within the tumor-infiltrating CD4\_4 cluster, we observed increased expression of the Th1 driver *TBX21* (T-bet), activation marker *LAG3* and *NR4A2* and cytokine expression (Figure 4c). Both CD4\_5 and CD4\_7 had expression of regulatory T (Tregs) cell markers (Figure 4c), with higher levels of *FOXP3*, *IL2RA* (CD25), *CTLA4* and *TNFRSF18* (GITR) in the tumor-predominant CD4\_5 (Figure 4c).

Constructing the cell trajectory curves based on the CD4+ subclustering, we observed two root points of the *CCR7*+ *SELL*+ *TCF7*+ Clusters CD4\_1 and CD4\_3 leading to a common CD4\_4 termination (Figure 4d). Unlike the other CD4+ T cells, the curve generated for Tregs was divergent, starting at CD4\_5 through CD4\_7 and into CD4\_4 (Figure 4d). This likely represents a distinct expression pattern for Tregs (shared by CD4\_5 and CD4\_7) compared to other tumor-infiltrating CD4+ T cells. In addition, compared to the CD8+ subclustering, modest clonal expansion was seen in CD4\_4 and CD4\_5 and was not a clear pattern for cell trajectory (Figure 4e). With the common termination point for the curves at Cluster CD4\_4, we next wanted to examine if there are common markers for CD4+ T cell infiltration in ccRCC by comparing tumor-infiltering to peripheral-blood CD4+ T cells. Within the tumor-infiltrating CD4+ T cell, 203 genes adjusted p-value < 0.05, log-fold change ≥ 0.5 and ∆ cell percent > 10% (Supplemental Data 2). Upregulated within the tumor-infiltrating CD4+ T cells were heat shock proteins (*HSPA1A* and *HSPA1B*), Jun and FOS constituents (*FOS*, *JUN*, *JUNB*), MHC-II molecules (HLA-DRB), and secreted molecules (*CCL5*, *GZMA*, *GZMK*) (Figure 4f). Several of the upregulated genes are shared across all the tumor-predominant CD4 Clusters (Figure 4f); however, each cluster also had unique expression markers. Both CD4\_2 and CD4\_4 had increased levels of *IFNG* (Figure 4f), but CD4\_2 was enriched for heat shock proteins, while CD4\_4 had cytotoxic component and there was expression of *CD8A*, which likely represents modest contamination of CD8+ T cells (Figure 4f). The tumor-infiltrating Tregs, CD4\_5, had high levels of *CTLA4*, GITR (*TNFRSF18*) and *TIGIT*. In addition CD4\_5 had the highly-specific expression *CCR8* and *LAYN*, corresponding to previous reports.45,46 The CD4\_6 cluster had increased expression of the IL-6 cytokine, *OSM6*, and *AREG* and *SOCS3*, downstream of interleukin signaling (Figure 4f). The differential expression closely matched the pathway analysis, with CD4\_4 enriched for cytolytic and type I interferon signaling (Figure 4g). The CD4\_5 and CD4\_7 Treg cluster had preferential enrichment for metabolic pathways, with high levels of terminal differentiation in tumor-infiltrated CD4\_5 (Figure 4g). The *OSM*high CD4\_6 was enriched for IL-6/JAK/STAT3 signaling and inflammatory response genes (Figure 4g).

*Prominent infiltrating macrophages in ccRCC have transcriptional divergence.*

With the previous observation of an overall increase in macrophages and decreased monocytes in the integrated UMAP (Figure 1e), we next focused on differential analyses of the myeloid populations (Figure 5a). Across monocytes, macrophages and dendritic cells, subclustering found 20 distinct clusters (Figure 5a). Tissue-specific distribution was observed, with the majority tumor-infiltrating myeloid cells in subclusters 0, 3, 7, 8 and 15 (Figure 5b). In contrast, both normal kidney parenchyma and peripheral blood were comprised of a majority of monocytic subclusters (Figure 5b). Populations were assigned using canonical markers and in addition to the previously described singleR approach with macrophage subclusters (0, 3, 7, 13 and 14) identified using markers such as *CD1C*, *CLEC10A* (CD301), *FCER1A*, and *MSR1* (Figure 5c). In total, we observed a decreased proportion in CD14+ monocytes in tissue-infiltrating myeloid cells compared to peripheral blood and an increase in macrophages (Figure 5d). Normal renal parenchyma had a variable increase in CD14- CD16- monocytes, which was not significant (Figure 5d). As previously seen, we found a small number of DC (subclusters 15, 16, and 19) with distinct expression profiles associated with conventional DC1 (cDC1), plasmacytoid DC (pDC), and monocyte-derived DCs (moDC), respectively (Supplemental Figure 4).

Next we isolated the five macrophage subclusters, relabeling them tumor-associated macrophage 1 (TAM\_1), TAM\_2, TAM\_3, resident macrophage (rM) and peripheral macrophage (pM) based on the relative percent of cells derived from the respective tissue (Figure 5e). Although similar in distribution along the UMAP, which preserves global structure of expression, these five clusters had distinct expression patterns (Figure 1e, 5e). For example, the CD88high (*C5AR1*) CD54+ (*ICAM1*) TAM\_1 expressed increased levels of chemokines and cytokines, like *CCL3*, *CCL4*, *CXCL2*, and *IL10*; CD64high (*FCGR1A*) CD16high (*FCGR3A*) TAM\_2 subcluster expressed the apolipoprotein gene *APOE*, lysosomal lipase (*LIPA*), and ferroportin (*SLC40A1*); and *CD1C*high *CD86*+ TAM\_3 had high levels of *IL1R2* and Langerhin (*CD207*), a marker of the skin-resident Langerhan cells (Figure 5f). The pM subcluster had the highest level of the cell adhesion molecules *CLEC10A*, *SELL* (CD62L), and *ITGB7*, which can dimerize with *ITGA4* (CD49d) or *ITGAE* (CD103). Like the CD8+ T cells, we built cell trajectories based on varied genes and found two distinct curves converging into TAM\_3 and pM (Figure 5g). In order to assess potential functional differences for the macrophages, we performed gene set enrichment analysis (Figure 5h). As previously observed in single-cell data,25 no subclusters were distinctly M1 or M2 polarized. For example, TAM\_1 had enrichment for gene sets commonly associated with the M2 macrophage compartment, such as angiogenesis and the production of lipid mediators, while also having the highest levels of TNFɑ signaling enrichment, a common M1 macrophage characteristic. Across the three TAM subclusters, modest enrichment in both type 1 and type 2 interferon signaling was observed (Figure 5h). The non-TAM subclusters, rM and pM, had relatively lower levels of enrichment with the exception of proinflammatory signaling and glycolysis, respectively (Figure 5h). We also found an increase in antigen processing and presentation of lipid antigens via MHC-I in TAM\_2 and TAM\_3, while TAM\_1 had higher enrichment for polysaccharide antigens (Supplemental Figure 5).

*Differential prognostic significance in CD8+ T cell and TAM subclusters.*

These data demonstrate transcriptional differences in CD8+ T cells and TAMs in ccRCC. To determine if these transcriptional differences led to functional differences in tumor response, we investigated whether gene signatures can be developed from our SCRS data with prognostic values (Figure 6a). Using the Cancer Genome Atlas dataset for ccRCC,19 we separated the cohort in half, yielding a training and testing set. We isolated significantly upregulated genes from each subcluster of CD8+ T cells and macrophages selecting the top models for each cell type based on training results. Interestingly, we saw a consistently high performance for overall survival discrimination in CD8\_6 and TAM\_3-based signatures across all models we trained and different sizes of gene signatures. Applying the models to the testing cohort of 267 primary tumors, we found that both signatures had strong performance and categorized roughly 25% of ccRCC into poor prognostic groups and equating to hazard ratios of 3.44 and 2.59, respectively (Figure 6b). We also observed that the poor-prognosis predictions were associated with increasing histological grades (Figure 6c). There was not a clear association in expression by histological grade across genes in each signature (Supplemental Figure 6). However, there was a significant association between the CD8\_6 and TAM\_3 classifications, which shared a high degree of overlap in patients classified into good-prognosis (188 in both signatures) and poor-prognosis (35 in both signatures), Fisher p-value = 9.3e-15. Interestingly despite this close association, the CD8\_6 signature was more broadly applicable in discriminating overall survival across TCGA data sets (Supplemental Figure 7).

Moving beyond mRNA expression, we wanted to see if we could identify the proliferative CD8\_6 subcluster in tumor samples. Using mass cytometry data for T cells isolated from 4 healthy tissue samples, 68 ccRCC primary tumors, and 4 ccRCC metastasis, we identified a PD-1+ Ki-67Hi subset in 14.6% of a CD45+ CD3+ CD8+ T cells (Figure 6d). The majority of CD45+ CD3+ CD8+ T cells were either PD-1+ Ki-67- (42.4%) or PD-1- Ki-67- (39%) (Figure 6d). In addition to PD-1, this proliferative subset of CD8+ T cells in ccRCC had increased levels of CTLA-4, ICOS, 4-1BB (CD137), TIM-3, HLA-DR, and CD38 compared to the other CD45+ CD3+ CD8+ T cells (Figure 6e). Calculating the proportion of PD-1+ Ki-67Hi cells to total CD8+ T cells by sample, we categorized samples into thirds. We observed a similar distribution to the CD8\_6 gene signature assignments of the highest tertile for PD-1+ Ki-67Hi cells in more advanced histological grades (Figure 6f).

**Discussion**

With the improved understanding on how immunotherapies work, the phenotypic and functional profile of immune cells in the tumor microenvironment is now well known to influence prognosis and disease outcome. Comprehensive knowledge of gene signatures to fully understand the roles of specific immune populations in cancer is of high pathological relevance; not only in identifying dysregulated immune determinants of cancer progression, but also as a useful tool for selecting patients, evaluating the likelihood of benefit from immunotherapy and further identifying clinically significant subpopulations.

Despite immunotherapy being a mainstay of treatment for advanced and treatment-naive ccRCC, 3,47,48 ccRCC tumors have numerous counterintuitive immune findings compared with other immunotherapy-responsive tumors.49 For example, unlike other tumors that respond to immune checkpoint blockade, ccRCC has a relatively low tumor mutational load, which is thought to drive T-cell infiltration,19,50 and mutational burden in ccRCC is not associated with response to anti-PD-1 therapy.15 Moreover, despite this low mutational burden, ccRCC has the highest T cell infiltration score among tumor types within the TCGA.51 Similarly, therapeutic responses to anti-PD-1 therapy have been correlated with HLA heterozygosity in lung cancers and melanoma,52 which does not seem to be the case for ccRCC.15 Taken together, these disparate findings suggest a more complex interrelationship of the immune compartment for ccRCC tumors. While a few recent studies have explored human ccRCC at a single-cell level,30,42,53,54 the technique has not yet been applied to tumor-infiltrating immune cells to characterize the global transcriptional immune and T cell receptor landscape along with underlying mechanisms contributing to this unique tumor environment.

T cells are recognized as key effectors of the adaptive anti-tumor immune response. Several studies have demonstrated association of these cells with an unfavorable response to therapy and poor patient survival in ccRCC.6,13 In a comprehensive study, T cells represented the dominant lymphocytic population in most ccRCC cases and B cells were rarely detected,23 consistent with our findings of increased CD4+ and CD8+ T cells (Figure 1). We found that the blood CD8+ T cells are non-heterogeneous and poorly reflect tumor-infiltrating CD8+ T cell transcriptional profiles (Figure 3a,d). Organizing the structure of the CD8+ T cell manifold, we found four distinct branches that may represent transcriptional states upon tumor-infiltration, two associated with a PD-1+ TIM-3+ exhausted subcluster, a proliferative subcluster, and a fourth with the higher levels of cytokine signaling (Figure 3e,g). The latter cluster, CD8\_7 was also unique with minimal overlap in clonotypes compared to the other tumor-infiltrating predominant subcluster. Recent single-cell analyses in melanoma showed CD8+ T cells with lower activation and exhausted expression patterns were associated with improved anti-PD-1 responses.22 These responsive T cells had minimal shared clonotypes, similar to CD8\_7.22 Other studies have found the ccRCC tumors polyclonal CD8+ T cells with an “immune-regulated” phenotype and lower cytotoxicity compared to tumors with oligoclonal CD8+ T cells.55 Recent SCRS studies of pre- versus post-treatment of anti-PD-1 in basal cell carcinoma have found increased number and clonal expansion of CD39+ CD8+ T cells after immunotherapy.56 However, CD39+ CD8+ T cells in ccRCC have been shown to be associated with increased pathological stage and poor overall survival.57 Based on gene expression, our CD8\_0 and CD8\_6 subclusters closely fit this population of cells and these clusters had 57% and 46.5% of cells from the advanced-stage Patient 3, respectively. In developing the CD8 signature, we found that the model discriminated overall survival, but also was associated with increasing histological grade, suggesting that more aggressive histological features are also correlated with a unique transcriptional response (Figure 6b,c). Interestingly, patients with higher numbers of CD39+ CD8+ T cells had improved responses to sunitinib, a multi-tyrosine kinase inhibitor, suggesting that evaluation of exhausted phenotype for CD8+ T cells may help in clinical decision making or therapy selection.57 This is particularly interesting as we found shared CD8+, but not CD4+, T cell clonotypes in the corresponding peripheral blood of ccRCC patients (Figure 2). Although we find a stable overlap coefficient of around 13% for CD8+ clonotypes, more work is needed to assess the dynamics of infiltration versus exfiltration on the CD8+ T lymphocytes into the tumor bed.

The exhausted CD8+ T cell phenotype has been associated with advanced histological features and increased risk of disease progression,51,55,57 increased dysfunctional DC,6 and increased macrophage populations.18 However, controversy surrounds the role of myeloid populations in ccRCC tumor prognosis and progression. This may, in part, be a result of transcriptional and phenotypic plasticity of tumor-infiltrating myeloid cells.18,25 Our analysis demonstrated distinct CD16+ myeloid population derived within tumor compared to peripheral blood or normal renal parenchyma and an overall increase in tumor-associated macrophages (Figure 5a, d). M2 markers, like CD163 and CD204, have been associated with poor clinical outcomes in ccRCC18,58 and were the highest in the TAM\_1 and TAM\_2 subclusters (Figure 5g). This is despite no clear identification of canonical M1 or M2 macrophages subclusters (Figure 5h). Model training for gene signatures for TAMs found better overall discrimination using genes derived from TAM\_3 (Figure 6b), a subcluster that was unique for having lower levels of gene enrichment for M2 macrophages, angiogenesis, and lipid mediator production (Figure 5h). The TAM\_3 classification had an independently high degree with the CD8\_6, suggesting the possible interaction or coordination between lymphoid and myeloid cells in ccRCC. The increased immunogenicity of ccRCC has been tied to upregulation of the antigen presenting machinery expression through MHC-I.51 Across the myeloid subclustering, there was gene enrichment for MHC class I processing and presentation machinery in the DC subsets, while the macrophages had increased MHC class II enrichment (Supplemental Figure 5). Although several distinct DC populations were detected and there was a trend for increase in cDC1 subset (subcluster 15) with known function of tumor antigen cross-presentation, further analysis was limited by the total number of DCs isolated.

Our strategy of single cell analysis performed on immune cells taking into consideration the frequencies of lymphoid and myeloid cells during flow sorting provides a powerful way to identify the relationship between proportion of cell types and corresponding immune cell states. With the population structure and gene programs defined in our study for multiple immune populations, we showed that though the patients showed variable proportions of lymphoid and myeloid in each cell state, the number of states remain limited. Our study has limitations, including the small total number of samples (n=7), the rarity of certain cell populations, and the need for further functional characterizations of these immune populations. However, taken together, we provide a transcriptional and clonotypic map of ccRCC immune cells that in hope to gain insight into biomarkers and therapeutic targets in ccRCC.

Data3Data48

Data5

*s and Reproducibility*

Boxplots display 1.5-times the interquartile range unless otherwise indicated.

**A**

**Acknowledgments**

We thank Michael Knudson, Rita Sigmund, Joe Galbraith, Janice Cook-Granroth, Bethany Kilburg and Celeste Charchalac from University of Iowa Carver College of Medicine, Tissue Procurement Core (TPC) and Genito-Urologic Tissue Repository (GUMER) for receiving biological samples and clinical data. We thank Justin Fishbaugh, Heath Vignes and Michael Shey from the University of Iowa Flow Cytometry Facility. We thank Kevin Knudtson, Mary Boes, Garry Hauser and Mari Eyestone from the Iowa Institute of Human Genetics (IIHG) Genomics Division for planning and assisting use of Next Gen Sequencing (NGS) platforms, Diana Kolb from the IIHG Bioinformatics Division and the University of Iowa High Performance Computing (HPC) facility.

**Author contributions**

**Conception and design:** AV, YZ, WZ

**Development of methodology:** AV NB WZ

**Acquisition of data:** KN, YZ, AV

**Analysis and interpretation of data:** NB AV AS RWJ WZ YZ

**Writing, review, and/or revision of the manuscript:** AV NB AS RWJ WZ YZ

Supervision: YZ, WZ, RWJ

**Declaration of interests**

Dr. Russell W. Jenkins has a financial interest in XSphera Biosciences Inc., a company focused on using ex vivo profiling technology to deliver functional, precision immune-oncology solutions for patients, providers, and drug development companies. Dr. Jenkins’ interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. Other authors declare no competing interests.

**References**

1. Saad, A. M. *et al.* Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study. *Clin. Genitourin. Cancer* **17**, 46–75 (2019).

2. Koneru, R. & Hotte, S. J. Role of cytokine therapy for renal cell carcinoma in the era of targeted agents. *Curr. Oncol.* **16**, S40 (2009).

3. Motzer, R. J. *et al.* Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N. Engl. J. Med.* **380**, 1103–1115 (2019).

4. Dudani, S. *et al.* First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). *J. Clin. Oncol.* **37**, 584–584 (2019).

5. Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. *Cell* **161**, 205–214 (2015).

6. Giraldo, N. A. *et al.* Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. *Clin. Cancer Res.* **21**, 3031–3040 (2015).

7. Tumeh, P. C. *et al.* PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* **515**, 568–571 (2014).

8. Galon, J. *et al.* Immunoscore and Immunoprofiling in cancer: An update from the melanoma and immunotherapy bridge 2015. *J. Transl. Med.* **4**, (2016).

9. Ziai, J. *et al.* CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis. *PLoS One* **13**, e0190158 (2018).

10. Shimizu, S. *et al.* Tumor-infiltrating CD8+ T-cell density is an independent prognostic marker for oral squamous cell carcinoma. *Cancer Med.* **8**, 80–93 (2019).

11. Borcherding, N. *et al.* Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. *J. Mol. Biol.* **430**, 2014–2029 (2018).

12. Patel, H. D. *et al.* The future of perioperative therapy in advanced renal cell carcinoma: How can we PROSPER? *Futur. Oncol.* **15**, 1683–1695 (2019).

13. Nakano, O. *et al.* Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. *Cancer Res.* **61**, 5132–5136 (2001).

14. Baine, M. K. *et al.* Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. *Oncotarget* **6**, 24990 (2015).

15. Braun, D. A. *et al.* Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. *Nat. Med.* **26**, 909–918 (2020).

16. Choueiri, T. K. *et al.* Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). *J. Clin. Oncol.* **37**, 101 (2019).

17. Choueiri, T. K. *et al.* Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. *Lancet Oncol.* **19**, 451–460 (2018).

18. Chevrier, S. *et al.* An Immune Atlas of Clear Cell Renal Cell Carcinoma. *Cell* **169**, 736–749 (2017).

19. Creighton, C. J. *et al.* Comprehensivemolecular characterization of clear cell renal cell carcinoma. *Nature* **499**, 43–49 (2013).

20. Van Den Heuvel, C. N. A. M. *et al.* Molecular profiling of druggable targets in clear cell renal cell carcinoma through targeted RNA sequencing. *Front. Oncol.* **9**, 117 (2019).

21. Savas, P. *et al.* Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. *Nat. Med.* **24**, 986–993 (2018).

22. Sade-Feldman, M. *et al.* Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. *Cell* **175**, 998–1013 (2018).

23. Geissler, K. *et al.* Immune signature of tumor infiltrating immune cells in renal cancer. *Oncoimmunology* **4**, e985082 (2015).

24. Chung, W. *et al.* Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. *Nat. Commun.* **8**, 1–12 (2017).

25. Azizi, E. *et al.* Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. *Cell* **174**, 1293–1308 (2018).

26. Guo, X. *et al.* Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. *Nat. Med.* **24**, 978–985 (2018).

27. Tirosh, I. *et al.* Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. **352**, 189–196 (2016).

28. Beausang, J. F. *et al.* T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire. *Proc. Natl. Acad. Sci. U. S. A.* **114**, e10409-10417 (2017).

29. Zheng, C. *et al.* Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. *Cell* **169**, 1342–1356 (2017).

30. Young, M. D. *et al.* Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. *Science.* **361**, 594–599 (2018).

31. Baldan, V., Griffiths, R., Hawkins, R. E. & Gilham, D. E. Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. *Br. J. Cancer* **112**, 1510–1518 (2015).

32. Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888–1902 (2019).

33. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* **36**, 411–420 (2018).

34. Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. *Genome Biol.* **20**, 1–15 (2019).

35. Nestorowa, S. *et al.* A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation. *Blood* **128**, e20-31 (2016).

36. Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat. Immunol.* **20**, 163–172 (2019).

37. Dunham, I. *et al.* An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57–74 (2012).

38. Borcherding, N. & Bormann, N. L. scRepertoire: An R-based toolkit for single-cell immune receptor analysis. *F1000Research* **9**, 47 (2020).

39. Street, K. *et al.* Slingshot: Cell lineage and pseudotime inference for single-cell transcriptomics. *BMC Genomics* **19**, 477 (2018).

40. Liu, J. *et al.* An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell* **173**, 400–416 (2018).

41. Lähnemann, D. *et al.* Eleven grand challenges in single-cell data science. *Genome Biol.* **21**, 1–35 (2020).

42. Wu, T. D. *et al.* Peripheral T cell expansion predicts tumour infiltration and clinical response. *Nature* **579**, 274–278 (2020).

43. Luecken, M. D. & Theis, F. J. Current best practices in single‐cell RNA‐seq analysis: a tutorial. *Mol. Syst. Biol.* **15**, (2019).

44. Barbie, D. A. *et al.* Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature* **462**, 108–112 (2009).

45. Plitas, G. *et al.* Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. *Immunity* **45**, 1122–1134 (2016).

46. De Simone, M. *et al.* Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. *Immunity* **45**, 1135–1147 (2016).

47. Motzer, R. J. *et al.* Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. *N. Engl. J. Med.* **378**, 1277–1290 (2018).

48. Motzer, R. J. *et al.* Nivolumab versus everolimus in advanced renal-cell carcinoma. *N. Engl. J. Med.* **373**, 1803–1813 (2015).

49. Vuong, L., Kotecha, R. R., Voss, M. H. & Hakimi, A. A. Tumor microenvironment dynamics in clear-cell renal cell carcinoma. *Cancer Discov.* **9**, 1349–1357 (2019).

50. Miao, D. *et al.* Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science.* **359**, 801–806 (2018).

51. Şenbabaoğlu, Y. *et al.* Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. *Genome Biol.* **71**, 1–25 (2016).

52. Chowell, D. *et al.* Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. *Science.* **359**, 582–587 (2018).

53. Kim, K. T. *et al.* Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. *Genome Biol.* **17**, 1–17 (2016).

54. Zhou, W. *et al.* Comprehensive Analysis of Copy Number Variations in Kidney Cancer by Single-Cell Exome Sequencing. *Front. Genet.* **10**, 1379 (2020).

55. Giraldo, N. A. *et al.* Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. *Clin. Cancer Res.* **23**, 4416–4428 (2017).

56. Yost, K. E. *et al.* Clonal replacement of tumor-specific T cells following PD-1 blockade. *Nat. Med.* **25**, 1251–1259 (2019).

57. Qi, Y. *et al.* Tumor-infiltrating CD39+ CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients. *Cancer Immunol, Immunother* 1565–1576 (2020).

58. Komohara, Y. *et al.* Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. *Cancer Sci.* **102**, 1424–1431 (2011).

**Figure Legends**

**Figure 1: Single-cell RNA sequencing results from immune cells in ccRCC.** **a**. UMAP of 37,055 primary immune cells of peripheral blood, normal renal parenchyma and tumor-infiltrating ccRCC patients. **b**. Distribution of cells by tissue type, peripheral blood (blue), tumor (red), and kidney (light blue). Arrows indicated potential enriched or unique immune cells populations for tissue type. **c**. Percent of cells expressing canonical immune cell markers across the UMAP. **d**. Normalized correlation values for predicted immune cell phenotypes based on the SingleR R package for each cluster; dendrogram based on Euclidean distance. **e**. UMAP demonstrating inferred immune cell types in ccRCC, clusters are colored by cell type and proportion of single-cell per sequencing run by tissue type. P values based on one-way ANOVA; lack of labeled p-values equates to value > 0.05.

**Figure 2: Clonal dynamics vary by T cell types and patients.** **a.** UMAP of 37,055 primary immune cells overlaid with the frequency of clonotypes assigned by sample identification. **b.** Occupied repertoire space for the indicated clonotype groups for CD8+ and CD4+ T cells by sample and tissue type in ccRCC patients. **c**. Clonal overlap quantification by overlap coefficient for CD8+ and CD4+ T cells by sample and tissue type in ccRCC patients. **d**. The top 10 clonotypes for each patient as a relative proportion of clonotypes for corresponding peripheral or tumor populations. Each color represents a unique clonotype by patient. **e**. Distribution of clonotypes by tissue, UMAP cluster and ccRCC patient with highlighted (red) the top 2 clonotypes, comprising tumor-specific clonotypes across all clusters.

**Figure 3: CD8+ T cells in ccRCC tumors exhibit a transcriptional continuum with distinct populations. a.** UMAP subclustering of CD8+ T cells (original clusters 1, 8, 9, and 17). **b**. UMAP distribution of single cells by tissue type with relative and absolute percent of cells by tissue in each cluster. **c**. Cell cycle regression assignments for CD8+ T cells by cluster assignment. **d**. Percent of cells expressing selected markers for T cell biology. **e**. CD8+ UMAP of clusters (upper panel) and clonotype frequency (lower panel) overlaid with slingshot-based 39 cell trajectory starting at CD8\_4 and proceeding into 5 distinct curves: branch 1 (B1), B2, B3, B4, and B5. **f**. Clonotype overlap coefficients between subclusters. **g**. Z-transformed normalized enrichment scores from ssGSEA for selected gene sets by subcluster. **h**. Normalized enrichment scores for therapeutic response or lack of response to anti-PD-1 therapy across the CD8+ T cells (upper panel) and by pseudotime of each branch (lower panel).

**Figure 4: Single-cell CD4+ T cell characterization within ccRCC.** **a**. UMAP subclustering of CD4+ T cells (original clusters 4, 6, 10, 13, 15, and 20). **b**. UMAP distribution of single cells by tissue type with relative and absolute percent of cells by tissue in each cluster. **c**. Percent of cells expressing selected markers for T cell biology. **d**. CD4+ UMAP of subclusters (upper panel) and clonotype frequency (lower panel) overlaid with slingshot-based 39 cell trajectory starting from CD4\_1 (root 1) and CD4\_3 (root 2) with relative pseudotime for all curves calculated using slingshot. **e**. Occupied repertoire space for CD4+ subclusters. **f**. Top 10 markers for TI-predominant CD4+ subclusters. Size of points are relative to percent of cells in the subcluster expressing the indicated mRNA species. **g**. Z-transformed normalized enrichment scores from ssGSEA for selected gene sets by subcluster.

**Figure 5: Single-cell myeloid characterization in ccRCC.** **a**. UMAP subclustering of myeloid cells (original clusters 4, 6, 10, 13, 15, and 20). **b**. UMAP distribution of single cells by tissue type with relative percent of cells by tissue in each cluster. **c**. Percent of cells expressing selected markers for myeloid and macrophage markers. P-values derived from one-way ANOVA testing. **d**. Proportion of assigned cell types compared to total antigen presenting cells by tissue type. **e**. Macrophage subclusters: tumor-associated macrophage 1 (TAM\_1) (n=1,262), TAM\_2 (n=840), TAM\_3 (n=594), peripheral macrophage (pM) (n=275), and resident macrophage (rM) (n=194) with relative and absolute percent of cells by tissue in each cluster. **f**. Top differential expression markers for macrophage subclusters. **g**. Macrophage UMAP overlaid with slingshot-based39 cell trajectories starting at rM and TAM\_2 and proceeding into pM. Smaller UMAP shows pseudotime created by the cell trajectories. **h**. Z-transformed normalized enrichment scores from ssGSEA for selected gene sets by subcluster.

**Figure 6: Prognostic values of gene signatures derived from CD8+ T cell and TAM subclusters.** **a**. Schematic diagram of the machine-learning approach for signature development, selection and testing based on the k-nearest neighbors algorithm using the TCGA renal clear cell carcinoma data set. **b**. Kaplan-Meier curves for overall survival in testing subset for the CD8\_6 subcluster signature with corresponding distribution of histological grades by model assignment. **c**. Kaplan-Meier curves for overall survival in testing subset for the TAM\_3 subcluster signature with corresponding distribution of histological grades by model assignment with log-rank p-values. d. Density plots for 937,713 T cells isolated from 4 healthy samples, 68 primary ccRCC, 4 metastasis and quantified using mass cytometry.18 **e**. Markers with increased median expression in CD45+ CD3+ CD8+ PD-1+ Ki-67+ cells compared to other CD8+ cells. Adjusted p-values < 1e-12 for all indicated markers using Welch’s T-test. **f**. ccRCC primary tumor and healthy samples subdivided into tertiles by the proportion of CD45+ CD3+ CD8+ PD-1+ Ki-67+ relative to the entire CD45+ CD3+ CD8+ pool by histological grade.